Novo Nordisk A/S (NVO)
46.92
+0.18
(+0.39%)
USD |
NYSE |
Aug 24, 16:00
47.05
+0.13
(+0.28%)
After-Hours: 20:00
Novo Nordisk Enterprise Value : 171.54B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 171.54B |
| August 21, 2026 | 170.94B |
| August 20, 2026 | 168.93B |
| August 19, 2026 | 170.07B |
| August 18, 2026 | 167.49B |
| August 17, 2026 | 164.72B |
| August 14, 2026 | 168.09B |
| August 13, 2026 | 170.87B |
| August 12, 2026 | 169.77B |
| August 11, 2026 | 172.38B |
| August 10, 2026 | 174.25B |
| August 07, 2026 | 172.68B |
| August 06, 2026 | 168.36B |
| August 05, 2026 | 163.54B |
| August 04, 2026 | 162.71B |
| August 03, 2026 | 172.11B |
| July 31, 2026 | 172.08B |
| July 30, 2026 | 187.23B |
| July 29, 2026 | 187.13B |
| July 28, 2026 | 185.06B |
| July 27, 2026 | 180.74B |
| July 24, 2026 | 177.73B |
| July 23, 2026 | 175.76B |
| July 22, 2026 | 175.79B |
| July 21, 2026 | 179.77B |
| Date | Value |
|---|---|
| July 20, 2026 | 180.54B |
| July 17, 2026 | 182.92B |
| July 16, 2026 | 186.80B |
| July 15, 2026 | 183.72B |
| July 14, 2026 | 178.73B |
| July 13, 2026 | 179.44B |
| July 10, 2026 | 180.11B |
| July 09, 2026 | 178.10B |
| July 08, 2026 | 178.13B |
| July 07, 2026 | 180.64B |
| July 06, 2026 | 179.37B |
| July 02, 2026 | 183.29B |
| July 01, 2026 | 177.73B |
| June 30, 2026 | 174.95B |
| June 29, 2026 | 182.10B |
| June 26, 2026 | 181.19B |
| June 25, 2026 | 179.74B |
| June 24, 2026 | 178.97B |
| June 23, 2026 | 179.00B |
| June 22, 2026 | 173.81B |
| June 18, 2026 | 164.75B |
| June 17, 2026 | 165.86B |
| June 16, 2026 | 165.96B |
| June 15, 2026 | 167.21B |
| June 12, 2026 | 167.07B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 543.37B |
| Johnson & Johnson | 685.82B |
| Eli Lilly & Co. | 1.220T |
| Merck & Co., Inc. | 418.70B |
| Novartis AG | 330.99B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.265B |
| Revenue (Quarterly) | 12.21B |
| Total Expenses (Quarterly) | 8.946B |
| EPS Diluted (Quarterly) | 0.7362 |
| Gross Profit Margin (Quarterly) | 78.21% |
| Profit Margin (Quarterly) | 26.74% |
| Earnings Yield | 8.72% |
| Operating Earnings Yield | 11.19% |
| Normalized Earnings Yield | 9.072 |